Everolimus With or Without Bevacizumab in Patients With Advanced Kidney Cancer That Progressed After First-Line Therapy

Objectives: This randomized, open-label phase III trial asks whether adding bevacizumab (Avastin) to) everolimus (Afinitor) can improve overall survival of patients with advanced renal cell carcinoma that progressed after first-line vascular endothelial growth factor receptor (VEGFR)-tyrosine kinase inhibitor (TKI) treatment.

Key entry or exclusion criteria: Patients must have histologically confirmed renal cell carcinoma with some component of clear cell disease and their disease must be metastatic or unresectable. They also must have at least 1 prior VEGFR-TKI treatment and have progressed or been intolerant to treatment.

Locations: 400 sites.

Goal: 700 patients.

Study sponsor: Cancer and Leukemia Group B in collaboration with the National Cancer Institute.

Link for more information: clinicaltrials.gov/ct2/show/NCT01198158

NIH clinical trials identifier: NCT01198158.